BL-1210 / BL-1230

About BioLineRx

BioLineRx is an Israeli biopharmaceutical company dedicated to identifying, in-licensing, and developing promising therapeutic candidates, primarily in oncology. Its strategic focus is on advancing motixafortide, which has demonstrated potential in multiple clinical settings, including as a stem cell mobilizer for autologous transplantation and as a combination therapy for metastatic pancreatic cancer. The company leverages a lean operational model to advance its pipeline through clinical development and strategic partnerships.

Therapeutic Areas